NEXT Pharmaceutical Products Private Limited

Next Pharmaceutical Products Private Limited is a project of New Heights Investment Limited, an International Investment company, registered in British Virgin Island (BVI), established in collaboration with a group of professionals having years of diverse multinational experience. NEXT aspires to build a state of the art manufacturing facility in Pakistan in accordance with International GMP standards which is under construction at Sunder Estate, Lahore. NEXT was incorporated on July 23, 2009 under the Companies Ordinance, 1984. Based at Lahore, NEXT is committed to provide a wide range of high quality medicines at affordable prices to Pakistani and International market. In future NEXT intends to offer wide range of generic medicines. Some of them are life savers while others improve the quality of life for millions of people. Our medicines in pipeline would contribute to treat diseases in diverse fields such as cardiology, gastroenterology, metabolic diseases, internal medicine, orthopedic, gynaecology and surgery.

Elfin Drugs Private Limited

Elfin Drugs Private Limited is a consumer services company based out of E-206 Industrial Area Phase 8 B S.A.S. Nagar, Mohali, Punjab, India.

Glitz Pharma

Serving healthcare Since 1988 - GLITZ PHARMA is an established pharmaceutical concern involved in manufacturing of variety of formulations catering major therapeutic areas. GLITZ Pharma have a strong commitment towards humanity for delivering quality products at affordable prices & to continuously improve the effectiveness of Quality Management System. We consistently plan, implement, monitor and review the steps and procedures to improve on the quality of our materials, processes, equipment's and human resources. Our goal at “Glitz” is very simple; create value by providing the Best Medications to the Individuals across the Globe and spread health with care. We invest in our customers'​ success by listening and finding ingenious solutions. When our customers succeed, we all succeed. Expanding Our Reach, We are always looking for established companies across the globe to expand our reach with broad outlets covering countries / territories. Due to quality in our domain, companies from South-East Asia, North America, and West Africa have shown great interest and we are up-to the mark to establish our relations to potential buyers / distributors who do not sell cheap but have expertise to market our quality products with success. Our doors are open for new distributors-come-partners to expand internationally but ethically. For more information you can visit our Website or email us; info@glitzpharma.net / export@glitzpharma.net

orig pharmaceuticals private limited

ORIG PHARMACEUTICALS PRIVATE LIMITED is a pharmaceutical company based out of NO.18 JARAGNAHALLI, J.P. NAGAR 6TH PHASE, Bangalore, Karnataka, India.

Symbio Proinnovera

The newly announced merger of NY-headquartered Symbio LLC and CA-headquartered Dow Development Laboratories LLC with Munster (Germany)-based Proinnovera will form Symbio Proinnovera, creating one of the world’s largest specialized dermatology-focused clinical research organizations. Founded over 20 years ago, the Symbio & Dow Group has a full-service clinical trial CRO offering for dermatology, complemented by a business active in the pre-clinical formulation of topicals, providing its client's dermatology and aesthetics services - from pre-clinical formulation work to subsequent clinical trial execution. Proinnovera was founded 25 years ago and is a leading European CRO in the dermatology clinical trial space. It is a full-service CRO conducting clinical studies from Phase I to IV, as well as non-interventional and medical device studies. Proinnovera turns study data into oversight for clients to accelerate decision-making, increasing transparency and efficiency in the conduct of clinical trials. Both companies are proven market leaders among specialty dermatology CROs with exceptional geographical coverage. Their combined strength will enable them to excel at addressing customers’ needs and expectations in all areas of research. The newly formed organization will leverage the combined power of two highly experienced teams with deep expertise in the dermatology space to generate efficiencies and accelerate clinical research. Symbio Proinnovera will be supported in its growth by ARCHIMED, a leading investment firm focused exclusively on healthcare industries.